Content

• Cervical Cancer Vaccination Campaign Launched
• India’s Transformation into a Global Health Powerhouse

Cervical Cancer Vaccination Campaign Launched

Why in News? / Context

• On 28 February 2026, Government of India launched a nationwide free HPV vaccination campaign targeting 1.15 crore girls aged 14 years, marking a major preventive healthcare intervention under the Universal Immunisation Programme (UIP).
• India introduced single-dose HPV vaccination using Gardasil-4, achieving alignment with 160+ countries that have incorporated HPV vaccines into national immunisation schedules to advance the WHO cervical cancer elimination strategy.
• Programme implementation integrates U-WIN digital platform for beneficiary tracking and eVIN system for logistics management, strengthening transparency, accountability, and real-time vaccine supply monitoring across States and Union Territories.

Relevance

GS II – Polity & Social Justice

• Article 21 (Right to Health); Article 47 (public health duty).
• Cooperative federalism – Health under State List; UIP as Centrally Sponsored Scheme.
• Gender justice: India contributes ~25% of global cervical cancer deaths.
• Alignment with WHO 90–70–90 elimination target (SDG 3 & 5).

Practice Question

• “Cervical cancer elimination requires more than vaccination; it demands systemic public health reform.” Discuss in the Indian context.(250 Words)

II. Static Background – Cervical Cancer & HPV

1. Disease Burden

• As per GLOBOCAN 2022, cervical cancer recorded 6.6 lakh new global cases and 3.5 lakh deaths, making it the fourth most common cancer among women worldwide.
• India reports approximately 1.2 lakh new cases and nearly 80,000 deaths annually, accounting for about 25% of global cervical cancer deaths, reflecting disproportionate national burden and public health urgency.
• Cervical cancer primarily affects women in their productive and reproductive age group, generating intergenerational socio-economic impacts and contributing significantly to maternal orphanhood and household vulnerability.

2. Etiology & Transmission

• Cervical cancer is caused by persistent infection with Human Papillomavirus (HPV), a sexually transmitted virus, with high-risk oncogenic strains responsible for nearly all cases globally.
• In India, HPV types 16 and 18 account for more than 80% of cervical cancer cases, making targeted vaccination against these strains epidemiologically strategic and cost-effective.
• The disease exhibits a long latency period (10–20 years), creating a preventive window through vaccination before sexual debut and systematic screening in adulthood.

III. Vaccine & Scientific Dimensions

• India is administering Gardasil-4, a quadrivalent vaccine protecting against HPV types 6, 11, 16, and 18, covering both oncogenic and non-oncogenic strains linked to genital warts.
• Clinical evidence indicates 93–100% effectiveness against HPV types responsible for cervical cancer, with over 500 million doses administered globally since 2006, demonstrating strong safety and efficacy profiles.
• Adoption of a single-dose schedule, endorsed by WHO, enhances programme efficiency, affordability, and coverage, particularly in resource-constrained public health systems like India’s.

IV. Constitutional & Legal Dimensions

• Under Article 21, the Supreme Court has interpreted the Right to Life to include the Right to Health, obligating the State to undertake preventive healthcare measures.
• Article 47 (DPSP) mandates improvement of public health as a primary duty of the State, legitimising targeted vaccination drives for communicable and preventable diseases.
• Health falls under Entry 6, State List, requiring cooperative federalism, fiscal coordination, and uniform technical standards across diverse administrative capacities in States and Union Territories.

V. Governance & Administrative Dimensions

• Digital integration through U-WIN platform enables beneficiary registration, certification, and monitoring, strengthening transparency, real-time data analytics, and immunisation coverage mapping nationwide.
• eVIN (Electronic Vaccine Intelligence Network) ensures cold-chain integrity, stock visibility, and supply chain efficiency, minimising wastage and ensuring temperature-sensitive vaccine stability.
• Dedicated Adverse Events Following Immunisation (AEFI) management protocols, 30-minute post-vaccination observation, and linkage with 24×7 facilities improve public trust and mitigate vaccine hesitancy.

VI. Economic Dimensions

• Treatment of cervical cancer involves costly chemotherapy, radiotherapy, and surgical interventions, imposing catastrophic health expenditure burdens, especially on economically vulnerable households.
• Preventive vaccination offers significantly lower per-capita costs compared to tertiary treatment, generating long-term fiscal savings and improving cost-effectiveness ratios in public health investment.
• WHO modelling estimates achieving elimination targets could prevent 74 million new cases and avert 62 million deaths globally by 2120, underscoring macroeconomic productivity gains.

VII. Social & Ethical Dimensions

• Cervical cancer disproportionately affects women, making vaccination a matter of gender justice, health equity, and social empowerment, consistent with constitutional commitments to substantive equality.
• Approximately 20% of children who lose their mothers to cancer do so due to cervical cancer, reflecting broader social vulnerability and intergenerational disadvantage.
• Ethical governance requires countering misinformation regarding fertility or morality concerns through community engagement, informed consent practices, and culturally sensitive public health communication.

VIII. Public Health & SDG Linkages

• The programme aligns with WHO’s 90–70–90 targets by 2030: 90% girls vaccinated, 70% women screened, and 90% cases treated, aiming for elimination threshold below 4 cases per 1 lakh women.
• Contributes directly to SDG 3 (Good Health and Well-being) and indirectly to SDG 5 (Gender Equality) by reducing preventable mortality among women in reproductive age.

IX. Challenges & Gaps

• Current focus on 14-year-old girls only excludes boys, despite HPV’s association with oropharyngeal and anal cancers, raising questions on gender-neutral vaccination strategies.
• Screening infrastructure for HPV DNA testing and Pap smears remains uneven across rural India, limiting comprehensive prevention beyond vaccination coverage.
• Vaccine hesitancy, misinformation, cold-chain gaps in aspirational districts, and dependency on global supply chains may affect sustained programme effectiveness.

X. Way Forward

• Gradually expand vaccination to 9–14 age cohort through school-based models to maximise early-age coverage and reduce dropout rates.
• Integrate universal HPV DNA screening at PHC level under Ayushman Bharat, combining vaccination with early detection strategies.
• Promote indigenous manufacturing (e.g., Cervavac) under Atmanirbhar Bharat to ensure long-term supply security and affordability.
• Institutionalise behaviour change communication through ASHAs and Anganwadi workers, strengthening community-level trust and vaccine acceptance.

XI. Prelims Pointers

• HPV 16 & 18 are high-risk oncogenic strains causing majority of cervical cancers.
• Gardasil-4 protects against 6, 11, 16, 18; it is preventive, not therapeutic.
• Health is under State List, but UIP operates as a Centrally Sponsored Scheme.
• eVIN manages logistics; U-WIN records beneficiaries and certification.

XII. Concluding Analytical Insight

• The campaign represents a shift from curative to preventive healthcare, operationalising constitutional mandates, leveraging digital governance tools, and addressing one of India’s most significant gendered public health burdens.
• Sustained vaccination, combined with screening and awareness, can enable India to achieve the WHO elimination threshold within two decades, transforming women’s health outcomes structurally and irreversibly.

India’s Transformation into a Global Health Powerhouse

I. Why in News? / Context

• Government highlighted India’s emergence as a Global Health Powerhouse, citing expansion of Ayushman Bharat, pharmaceutical dominance, digital health infrastructure, and biotechnology growth aligned with Viksit Bharat 2047 vision.
• India now combines Universal Health Coverage (UHC), global vaccine leadership, AI-enabled public health systems, and a rapidly expanding $165.7 billion bioeconomy (2024) projected to reach $300 billion by 2030.

Relevance

GS II – Governance

• Ayushman Bharat (₹5 lakh cover; 434+ million cards).
• 1.84 lakh Arogya Mandirs – primary care focus.
• PM-ABHIM strengthens surveillance & critical care.

GS III – Economy & Security

• 20% global generic supply; 55–60% UNICEF vaccines.
• Bioeconomy: $165.7 bn (2024), target $300 bn by 2030.
• Medical tourism rise (112k → 600k).
• Pandemic preparedness & lab networks.

Practice Questions

• India’s emergence as the “Pharmacy of the World” has strategic, economic, and diplomatic implications. Analyse.(250 Words)

II. Constitutional & Policy Foundations

• Article 21 (Right to Life) judicially expanded to include Right to Health, forming constitutional basis for universal coverage, affordable medicines, and public financing of secondary and tertiary healthcare services.
• Article 47 (DPSP) mandates improvement of public health, nutrition, and living standards, legitimising schemes like Ayushman Bharat, National Health Mission (NHM), and expanded immunisation strategies.
• Health under State List (Entry 6) requires cooperative federalism, fiscal transfers, centrally sponsored schemes, and interoperable digital standards to ensure equity across States and aspirational districts.

III. Universal Health Coverage – Ayushman Bharat Architecture

1. Insurance Component – AB-PMJAY

• AB-PMJAY, launched 23 September 2018, provides ₹5 lakh annual coverage per family for secondary and tertiary care, targeting bottom 40% population, including all senior citizens above 70 years.
• Over 434 million Ayushman Cards issued, making it the world’s largest publicly funded health assurance scheme, significantly reducing catastrophic health expenditure among vulnerable households.
• Scheme generated ₹1.25 lakh crore savings (2024–25) for beneficiary families; Budget 2026–27 allocation ₹9,500 crore, reflecting sustained fiscal prioritisation and coverage expansion.

2. Primary Care – Ayushman Arogya Mandirs (AAMs)

• India has established 1,84,235 Ayushman Arogya Mandirs (2026) delivering comprehensive primary care, including preventive, promotive, and NCD services across rural, urban, tribal, and aspirational districts.
• Conducted 426.6 million teleconsultations (2025) and over 58 million wellness sessions, embedding preventive healthcare and community-based screening into grassroots health governance.
• Massive NCD screenings: 401.3 million hypertension, 398.6 million diabetes, 338.3 million oral cancer, and 158.6 million breast cancer screenings, strengthening early detection and reducing long-term disease burden.

3. Infrastructure Strengthening – PM-ABHIM

• PM-Ayushman Bharat Health Infrastructure Mission (2021) approved ₹32,928.82 crore (2021–26) to strengthen district-level surveillance, laboratories, critical care blocks, and block public health units.
• Targets creation/upgradation of 9,519 sub-centres, 2,151 block units, 744 integrated public health labs, and 622 critical care blocks, enhancing pandemic preparedness and outbreak response capacity.
• IT-enabled real-time disease surveillance integrates laboratory networks across block, district, regional, and national levels, improving early warning systems and health security resilience.

IV. Digital Public Health Infrastructure

• Ayushman Bharat Digital Mission (ABDM) created over 863 million ABHA IDs (2026), forming one of the world’s largest interoperable digital health ecosystems with secure health data access.
• Tele-MANAS operates 53 mental health cells across 36 States/UTs, providing 24×7 counselling in 20 languages, handling over 3.28 million calls, expanding mental health accessibility nationwide.
• AI integration through Strategy for AI in Healthcare for India (2026) institutionalises ethical AI adoption in diagnostics, triaging, predictive analytics, and digital prescription generation.

V. National Health Mission & Immunisation Strength

• NHM contributed to 83% decline in Maternal Mortality Ratio since 1990, outperforming global reduction of 45%, demonstrating sustained systemic improvement in reproductive health services.
• Under-5 Mortality reduced by 75% since 1990, exceeding global decline of 60%, reflecting improved immunisation, nutrition, and institutional delivery coverage.
• Universal Immunisation Programme (UIP) covers 26.7 million newborns and 29 million pregnant women annually, conducting over 13 million immunisation sessions with support of 1.03 million ASHAs.
• Zero-dose children declined from 0.11% (2023) to 0.06% (2024) under Mission Indradhanush, strengthening last-mile immunisation equity and social mobilisation effectiveness.

VI. Pharmaceutical & Vaccine Leadership – “Pharmacy of the World”

• India is the 3rd largest pharmaceutical producer by volume, supplying 20% of global generic medicines and exporting to nearly 200 countries and territories.
• Provides 55–60% of UNICEF’s vaccines, and over 70% of global anti-retroviral medicines, ensuring affordable access for Global South and enhancing global health diplomacy.
• Indigenous COVID-19 vaccines like Covaxin and Covishield demonstrated integrated R&D and mass production capacity, strengthening India’s credibility as a vaccine manufacturing hub.
• Bioeconomy expanded 13-fold from $10 billion (2014) to $165.7 billion (2024), projected $300 billion by 2030, supported by National Biopharma Mission and Biopharma SHAKTI (2026–27).

VII. Affordable Medicines & Equity

• Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) operates 17,990 Kendras, offering 2,000+ medicines at 50–90% lower prices, saving citizens ₹30,000 crore over decade.
• AMRIT Pharmacies (255 outlets) provide affordable high-end drugs and implants, reducing cost barriers for tertiary care and strengthening financial risk protection.

VIII. Medical Education & Human Capital

• India now has 23 AIIMS institutions, 2,045 medical colleges, and expanded MBBS seats by 130% (51,348 to 118,190), ensuring long-term specialist workforce availability.
• Postgraduate seats increased by 138% (31,185 to 74,306), addressing specialist shortages and enhancing tertiary care delivery across emerging medical hubs.

IX. Technology & Innovation

• i-DRONE initiative (ICMR) enables vaccine and sample transport in high-altitude and remote terrains, strengthening last-mile connectivity and reducing diagnostic delays.
• AI tools like MadhuNetrAI and TB predictive analytics reported 27% decline in adverse TB outcomes, demonstrating measurable improvements in disease management efficiency.

X. Economic & Strategic Dimensions

• Rising medical tourism from 112,000 (2009) to over 600,000 (2024) strengthens service exports and soft power, with Budget 2026–27 announcing 5 integrated medical hubs.
• Health sector contributes to productivity, demographic dividend realisation, and reduced poverty due to catastrophic health expenditure, supporting inclusive economic growth trajectory.

XI. Challenges & Gaps

• Public health expenditure remains near 2% of GDP, below OECD averages, necessitating sustained fiscal expansion to maintain universal coverage commitments.
• Urban–rural disparities, specialist shortages in aspirational districts, and digital divide may limit equitable access to advanced digital health innovations.
• Regulatory strengthening, pharmacovigilance, and quality control oversight essential to maintain global trust amid expanding pharmaceutical exports.

XII. Way Forward

• Increase public health spending toward 2.5% of GDP (National Health Policy target) to ensure sustainable universal coverage and infrastructure strengthening.
• Integrate primary care, AI diagnostics, telemedicine, and preventive screening into a unified continuum-of-care model to reduce long-term disease burden.
• Strengthen domestic R&D ecosystems and regulatory capacity to position India as a global biomanufacturing and innovation hub, not merely a volume producer.
• Enhance global health diplomacy through South-South cooperation, vaccine partnerships, and technology transfer initiatives aligned with SDG 3 and Global Health Security Agenda.

Concluding Analytical Insight

• India’s transformation reflects convergence of constitutional mandate, digital public infrastructure, pharmaceutical leadership, preventive healthcare expansion, and bioeconomic growth, positioning it as a model for equitable, scalable, and innovation-driven health systems.
• If sustained with higher public spending, regulatory strengthening, and inclusive digital expansion, India can emerge not only as the “Pharmacy of the World” but as a Global Architect of Affordable Universal Health Coverage.